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Edited by Miguel De la RosaAbstract Aminopeptidase B (AP-B) is a metallopeptidase that
removes basic residues from the N-termini of neuropeptide sub-
strates in secretory vesicles. This study assessed zinc regulation
of AP-B activity, since secretory vesicles contain endogenous
zinc. AP-B was inhibited by zinc at concentrations typically pres-
ent in secretory vesicles. Zinc eﬀects were dependent on concen-
tration, incubation time, and the molar ratio of zinc to enzyme.
AP-B activity was recovered upon removal of zinc. AP-B with
zinc became susceptible to degradation by trypsin, suggesting
that zinc alters enzyme conformation. Zinc regulation demon-
strates the metallopeptidase property of AP-B.
 2008 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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Proteolytic processing of prohormone and proneuropeptide
precursors is required for the biosynthesis of active peptide
hormones and neurotransmitters, known as neuropeptides.
We recently identiﬁed secretory vesicle cathepsin L as a pro-
neuropeptide processing enzyme for proenkephalin and others
[1,2]. Cathepsin L represents a novel cysteine protease pathway
for prohormone processing, in addition to the subtilisin-like
prohormone convertases 1 and 2 (PC1/3 and PC2) [3–5].
Cathepsin L processing of proenkephalin within secretory ves-
icles results in peptide intermediates containing basic residue
extensions at the NH2-termini. Subsequently, Arg/Lys amino-
peptidase is required to generate the mature enkephalin and re-
lated neuropeptides.
The Arg/Lys aminopeptidase activity in neuropeptide-con-
taining chromaﬃn secretory vesicles was identiﬁed as amino-
peptidase B (AP-B) by our recent molecular cloning studies
[6]. AP-B generates mature (Met)enkephalin (ME) from Arg-
ME and Lys-ME peptide intermediates [6]. Sequence analyses
of bovine and rat AP-B cDNAs [6–8] illustrate the presence of
the metal-binding HEXXH motif which is typical of membersAbbreviations: AP-B, aminopeptidase B; ME, (Met)enkephalin
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doi:10.1016/j.febslet.2008.06.017of metalloprotease families [9,10]. Most metalloproteases are
regulated by zinc metal ion, but a few metalloproteases, such
as methionyl aminopeptidase in Escherichia coli (M24 family
of metalloprotease) and aminopeptidase T from thermus
aquaticus (M29 family) utilize cobalt for activity [10]. Since
AP-B is present in secretory vesicles that are known to contain
zinc [11–13], it was of interest in this study to explore the reg-
ulation of AP-B by zinc.
This study evaluated the zinc metal ion dependence of AP-B.
Results indicated that at zinc concentrations representative of
in vivo levels in secretory granules, zinc inhibited AP-B at
micromolar concentrations (5–50 lM), but low levels of zinc
transiently activated AP-B. Kinetics for zinc inhibition of
AP-B was assessed. Zinc inhibition was reversible upon re-
moval of zinc. Furthermore, when incubated with inhibitory
levels of zinc, AP-B became sensitive to degradation by tryp-
sin, suggesting that zinc may alter the conformation of AP-B
in a manner that increased its susceptibility to proteolytic deg-
radation. The presence of micromolar concentrations of zinc
within secretory granules [11] implicates in vivo inhibition of
AP-B within secretory vesicles of endocrine and neuronal cells.
These ﬁndings for zinc regulation of aminopeptidase B demon-
strate its metalloprotease properties.2. Materials and methods
2.1. Expression and puriﬁcation of recombinant aminopeptidase B
(AP-B)
The rat AP-B cDNA [6] was expressed in E. coli, and puriﬁed by a
Ni2+ -column by aﬃnity binding to the N-His-tag of recombinant AP-
B, as we have described previously [6]. The resultant AP-B is enzymat-
ically active with Arg-MCA substrate used for monitoring AP-B activ-
ity. Puriﬁed AP-B was stored in 50% glycerol at 20 C.2.2. AP-B activity and regulation by zinc
AP-B was preincubated with 0–80 lM ZnCl2 for 5 min at room tem-
perature; Arg-MCA substrate was then added to a ﬁnal concentration
of 200 lM in the AP-B assay buﬀer (100 ll assay volume, containing
50 mM Tris–HCl, pH 7.5, 150 mM NaCl). Enzyme samples were incu-
bated at 37 C for 5–40 min, and AP-B activity was measured by the
release of ﬂuorescent AMC, as described previously [6]. Relative AP-
B activity in the presence of zinc was compared to control AP-B activ-
ity without zinc. AP-B activity was also assessed at diﬀerent molar ra-
tios of zinc to AP-B enzyme. Assays were conducted at pH 7.5 to allow
comparison to other studies of the eﬀects of zinc on metalloproteases;
AP-B activity at pH 7.5 represents approximately 80% of its activity
measured at pH 5.5–6.5 [6].
Kinetics of zinc inhibition of AP-B was evaluated by Lineweaver–
Burk plots [14] which showed mixed inhibition kinetics, which may
represent inhibitor binding to free enzyme ([E]) or the enzyme-sub-
strate complex ([ES]), respectively. Inhibitor binding to E and ES areblished by Elsevier B.V. All rights reserved.
Fig. 2. Zinc regulation of AP-B. Aminopeptidase B (AP-B, 22 nM)
was assessed at diﬀerent concentrations of ZnCl2 in time course assays
that monitored activity at 10, 15, 30, and 45 min of incubation. AP-B
activity was expressed as percent of control AP-B activity (100%)
assayed in the absence of zinc.
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K 0i ¼ ð½ES½IÞ=½ESI. Ki and K 0i can be calculated by a = 1 + [I]/Ki;
and a0 ¼ 1þ ½I=K 0i, with the Lineweaver–Burk plot equation repre-
sented by 1/v0 = (aKm/Vmax)(1/[S]) + a 0/Vmax [14]. Furthermore, the ef-
fect of zinc on the catalytic eﬃciency, kcat/Km, of AP-B was evaluated
[14].
All assays of AP-B under diﬀerent zinc conditions were performed in
duplicate or triplicate, and each experiment was repeated at least two-
three times. Based on the replicate assays for each condition tested for
AP-B activity, the averages of the activity assays are plotted in Figs. 1–
6. The average values for replicate assays varied by less than 5% of the
average enzyme activity value. Furthermore, the mean values of ami-
nopeptidase activities in the presence of zinc, compared to the absence
of zinc, were statistically signiﬁcant based on students t-tests with
P < 0.05 (for Figs. 1–5). Also, the mean values of aminopeptidase
activities with desalting were statistically signiﬁcant compared to the
enzyme activities without desalting (students t-test, P < 0.05) (Fig. 6).
2.3. Reversibility of zinc inhibition of AP-B
AP-B (22 nM) was incubated with 50 lM ZnCl2 for 5 min at room
temperature, and was then desalted on a Zebra desalting column (Pierce
Biotechnology, Rockford, IL). A second desalting step was included to
insure maximal removal of ZnCl2. AP-B activity before and after
desalting was monitored to assess the reversibility of zinc inhibition.
2.4. Susceptibility of AP-B to degradation by trypsin during incubation
with zinc
AP-B (120 nM) was incubated in AP-B assay buﬀer wth zinc
(250 lM ZnCl2) for 5 min. The buﬀer was exchanged to trypsin diges-
tion buﬀer (100 mM Tris–HCl, pH 7.5, 10 mM CaCl2, 0.005% Triton
X-100) by a desalting column. The AP-B sample was incubated with
or without trypsin (50 ng bovine trypsin, Worthington, Piscataway,
NJ) at 30 (for 40 min). The integrity of AP-B was then assessed by
western blots with anti-AP-B, as described previously [1,2,6].3. Results
3.1. Zinc regulation of AP-B
AP-B activity, measured with Arg-MCA as substrate, was
inhibited by increasing concentrations of ZnCl2 with nearlyFig. 1. Zinc inhibition of aminopeptidase B (AP-B) at in vivo levels of
zinc in secretory vesicles. AP-B activity was assessed at diﬀerent
concentrations of zinc of 5–80 lM ZnCl2). AP-B (22 nM) was
monitored with Arg-MCA substrate, with aminopeptidase activity
detected by the formation of ﬂuorescent AMC (aminomethylcouma-
rinamide). Results show inhibition of AP-B by zinc in a concentration-
dependent manner.
Fig. 3. Eﬀects of diﬀerent molar ratios of zinc to AP-B for
aminopeptidase activity. AP-B was assayed in the presence of ZnCl2
(0.5 lM) at diﬀerent molar ratios of 80, 40, and 20 of zinc to AP-B at
37 C for 60 min. The percent inhibition of AP-B relative to AP-B
control without zinc (0% inhibition) is shown. The mean of replicate
assays (triplicate) with S.E.M. (standard error of the mean) is shown.complete inhibition occurring at 50–80 lM (Fig. 1). These as-
says measured AP-B activity with Arg-MCA substrate for
30 min (37 C). Based on the estimated in vivo levels of zinc
in secretory vesicles of 10–50 lM [11], it is likely that AP-B
in secretory vesicles may be present in an inhibited condition
by zinc.
At lower levels of zinc and with shorter incubation times (10
and 15 min) low levels of zinc at 0.25–2 lM resulted in some
Fig. 4. Analysis of zinc inhibition of AP-B by Lineweaver–Burk plot.
Inhibition of AP-B (22 nM) by zinc (at 5, and 10 lM) was assessed by
inverse Lineweaver–Burk plots [15], which indicated zinc as a mixed
inhibitor. The Lineweaver–Burk plot also showed that AP-B (without
zinc) has Km value of 27 lM Arg-MCA and Vmax of 1.2 lM/min. The
Ki and K
0
i values for zinc inhibition of enzyme and enzyme/substrate
complexes were calculated as 6 and 12 lM zinc, respectively.
Fig. 5. Reversibility of zinc inhibition of AP-B. AP-B (22 nM) was
incubated with ZnCl2 (50 lM) for 5 min, and was then assayed for AP-
B activity with diﬀerent incubation times (2–75 min). AP-B activity
without removal of zinc (s), and after removal of ZnCl2 by one (m) or
two (h) desalting column steps, was assessed. Recovery of AP-B
activity is evident upon removal of ZnCl2.
Fig. 6. Zinc increases susceptibility of AP-B to degradation by trypsin.
Puriﬁed AP-B (835 ng) was incubated without (lane 1) or with (lane 2)
ZnCl2 (250 lM) (for 5 min), and was then subjected to incubation with
trypsin (50 ng) at 30 C for 40 min. The integrity AP-B was then
assessed by western blots with anti-AP-B, with equal amounts of AP-B
(58 ng) present in each of lanes 1 and 2. Results show that zinc induced
the susceptibility of AP-B to degradation by trypsin.
Table 1
Catalytic eﬃciency of aminopeptidase B in the absence and presence of
zinc
Zinc concentration (lM) kcat/Km of Aminopeptidase B (M
1 s1)
0 3.3 · l04
5 1.6 · 104
10 1.0 · l04
AP-B was evaluated for its catalytic eﬃciency by determining the kcat/
Km value in the absence or presence of ZnCl2 (5 and 10 lM).
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out zinc) (Fig. 2). However, the longer incubation times (30
and 45 min) result in inhibition of AP-B at ZnCl2 of greater
than 3 lM. In addition, inhibition of AP-B by zinc was shown
to depend on the molar ratio of zinc to enzyme (Fig. 3). Since
the in vivo levels of zinc in secretory vesicles is estimated at 10–
50 lM [11], it is predicted AP-B in these vesicles is largely
inhibited at in vivo levels of zinc.
Kinetic evaluation of zinc inhibition of AP-B by Linewe-
aver–Burk analysis (Fig. 4) showed zinc inhibition to display
properties of a mixed inhibitor [14]. A mixed inhibitor is
hypothesized to bind to the free enzyme (E) and the en-
zyme-substrate complex (ES). Thus, the Ki value for inhibi-
tion of E was calculated as 6 lM, and the K 0i value for
inhibition of ES was calculated as 12 lM zinc. In addition,
the presence of zinc reduced the catalytic eﬃciency of AP-B
assessed by its kcat/Km value. AP-B in the absence of zinc
showed a kcat/Km value of 3.3 · 10 M1 s1, which was re-
duced to 1.0 · 10 M1 s1 in the presence of 10 lM ZnCl2
(Table 1).
3.2. Reversibility of zinc inhibition of AP-B
After inhibition of AP-B by zinc, AP-B activity was recov-
ered after removal of zinc by a desalting column (Fig. 5).
Recovery of AP-B activity was facilitated by subjecting AP-B
to one or two desalting steps for removal of zinc. These results
demonstrate the reversible nature of zinc inhibition of AP-B.
3.3. Alteration of AP-B conformation demonstrated by zinc-
induced susceptibility to degradation by trypsin
After incubation of AP-B with ZnCl2 (250 lM), AP-B was
more susceptible to degradation by trypsin. In the absence of
ZnCl2, intact AP-B of 74 kDa was observed by western blots
after incubation with trypsin (Fig. 6, lane 1). However, the
presence of ZnCl2 (250 lM) resulted in AP-B degradation by
trypsin (Fig. 6, lane 2). These results suggest that ZnCl2 alters
the conformation of AP-B in a manner that facilitates its deg-
radation by trypsin. Thus, zinc inhibition of AP-B may involve
conformational changes in the AP-B enzyme.
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Aminopeptidase B (AP-B) is a metallopeptidase that re-
moves NH2-terminal basic residues (Arg, Lys) from peptide
substrates. AP-B was recently found to be localized within
neuropeptide-containing secretory vesicles for the production
of the (Met)enkephalin neuropeptide. AP-B is predicted to
be regulated by zinc metal ion for its activity, as predicted from
its HEXXH metallopeptidase motif. The presence of endoge-
nous zinc in neuropeptide-containing secretory granules [11–
13] that contain AP-B [6,15] raised the question of how AP-
B activity may be regulated by zinc.
Therefore, this study examined and demonstrated zinc regu-
lation of recombinant AP-B activity. AP-B was inhibited by
zinc at 5–50 lM and higher levels that represent in vivo levels
of zinc in secretory granules [11]. However, low levels of zinc
activated AP-B activity with short incubation times, but inhi-
bition was observed at longer incubation times. The regulatory
eﬀects of zinc were dependent on incubation time with AP-B,
and on the molar ratio of zinc to AP-B enzyme. Zinc inhibition
of AP-B was reversed by removal of zinc. In the presence of
inhibitory levels of zinc, AP-B became susceptible to degrada-
tion by trypsin, suggesting that zinc alters the relative confor-
mation of AP-B in a manner that facilitates trypsin
degradation. Zinc modulation of AP-B activity demonstrates
its metallopeptidase property, and implicates in vivo regula-
tion of AP-B activity by zinc.
Kinetic studies demonstrated zinc as a mixed inhibitor of
AP-B, demonstrated by the Lineweaver-Burk plot. Mixed inhi-
bition is hypothesized to represent inhibition of the enzyme,
AP-B, with calculation of Ki of 6 lM zinc, and inhibition of
the enzyme/substrate complex with a K 0i of 12 lM. Further-
more, evaluation of the catalytic eﬃciency of AP-B showed
that zinc reduced its catalytic eﬃciency from 3.3 · 10 M1 s1
in the absence of zinc, to 1.6 · 10 and 1.0 · 10 M1 s1 in the
presence of 5 and 10 lM zinc, respectively. These eﬀects of zinc
on AP-B, combined with the presence of zinc in secretory ves-
icles that contain AP-B, suggest that zinc may be involved in
the in vivo regulation of AP-B in secretory vesicles.
The role of zinc for regulation of AP-B in neuropeptide-con-
taining secretory vesicles is consistent with knowledge that zinc
is stored and released from presynatic vesicles of neurons [11]
which release peptide neurotransmitters [3]. Studies of endog-
enous release of zinc from synaptic vesicles estimates the
in vivo level of zinc to be 10–50 lM and greater. At this range
of zinc concentration, AP-B in secretory vesicles would be par-
tially inhibited by zinc, as shown in this study. Zinc is also
present in secretory granules of pituitary and pancreas that
store and secrete peptide hormones [12,13]. AP-B has been
demonstrated in such endocrine secretory vesicles [15]. Thus,
the presence of zinc in secretory vesicles of neuroendocrine
cells may allow zinc regulation of AP-B activity that is in-
volved in the production of peptide neurotransmitters and pep-
tide hormones.
AP-B has been proposed as an exopeptidase step in the
cathepsin L protease pathway for proteolytic processing of
proneuropeptides in secretory vesicles [3,6]. Following the pre-
ferred cleavage at the NH2-terminal side of dibasic processing
sites within proneuropeptides by cathepsin L, peptide interme-
diates contain basic residues at their NH2-termini. AP-B is
then required to remove NH2-terminal basic residues to gener-
ate the active neuropeptide. The presence of zinc within neuro-peptide-containing secretory vesicles suggests a metal ion
mechanism for the regulation of AP-B activity in this orga-
nelle.
In addition to AP-B, the carboxypeptidase E (CPE, also
known as carboxypeptidase H) is another metallopeptidase
utilized for neuropeptide production in secretory vesicles
[3,16]. CPE removes COOH-terminal basic residues of peptide
intermediates generated by proteolytic processing of proneuro-
peptides by the subtilisin-like prohormone convertases 1 and 2
(PC 1/3 and PC 2) [3–5]. Thus, both aminopeptidase and car-
boxypeptidase metallopeptidases are involved in secretory ves-
icle production of neuropeptides.
Studies of the metalloprotease carboxypeptidase A have also
demonstrated that high levels of zinc inhibit the carboxypepti-
dase activity [17,18], with zinc shown as competitive inhibitor
of CPA [19]. In addition, X-ray cyrstallography studies show
that a second zinc binds to the enzyme active site that may per-
turb substrate catalysis [20]. These interesting studies, how-
ever, diﬀer from zinc inhibition of AP-B shown in this
report, since zinc shows mixed inhibition kinetics for AP-B (in-
stead of zinc competitive inhibition of CPA). Furthermore, the
rat AP-B shows low primary sequence homology to bovine
CPA [21] of only 10.8%, although both contain the metal bind-
ing HEXXH motif; these comparisons show that AP-B diﬀers
substantially from the primary structure of bovine CPA. It will
be of interest in future studies to gain structural knowledge of
the mechanism for zinc inhibition of AP-B.
Importantly, this study has demonstrated that estimated
endogenous levels of zinc in secretory vesicles inhibits AP-B
metalloprotease activity. Thus, zinc within secretory vesicles
may represent an in vivo factor involved in the regulation of
AP-B activity for the production of neuropeptides that func-
tion as peptide neurotransmitters and peptide hormones.
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